Talk about unintended consequences of a patent ruling. Pfizer's unprecedented effort to fight Lyrica copies in England has doctors and pharmacists squabbling, and the National Health Service stepping in to keep the peace.
Generics makers aren't the only ones filing challenges to pharma patents anymore. Hedge funds are doing it, too, and it's got drugmakers on edge.
The U.S. Patent Office gives, and the U.S. Patent Office takes away. Unfortunately for Johnson & Johnson, it was the latter for Remicade. After a re-examination of Remicade's September 2018 patent, agency officials issued a big fat rejection.
Last month, Texas hedge fund manager Kyle Bass said he had pharma and its "questionable" patents in his sights. Now, he's made his first move--and he's said 14 more targets will follow.
Gilead Sciences might have expected a hepatitis C patent challenge in India. But in Europe? Not so much. But that's exactly what Gilead is getting. After losing its bid for a new Indian patent covering its blockbuster treatment Sovaldi, Gilead is now threatened with a similar action at the European Patent Office in Munich.
India's Cipla argued before the Delhi High Court against the Novartis patent for its Onbrez (indacaterol) COPD drug, saying the patent need not be honored because the Swiss drugmaker was not working it in the country and has licensed it to Lupin instead.
When the just-ended New York negotiations failed to resolve drug-patenting and other intellectual property issues, the focus shifted to a ministerial-level meeting of the Trans-Pacific Partnership expected to take place in March.
For the past couple of years, the pharma industry has had something of a reprieve from patent-cliff nightmares. But according to Moody's Investors Service, some companies face new threats to their sweet dreams.
SINGAPORE-- As soon as the Delhi High Court revived Gilead Sciences' patent hopes for Sovaldi, a new actor has come on the scene: Sankalp Rehabilitation Trust, which has joined three other plaintiffs in opposing the new patent.
Don't look for any Trans-Pacific Partnership agreement on patent lengths for biologics this year. That was the message delivered at a congressional hearing on Tuesday.